BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 27181912)

  • 1. Screening for circulating RAS/RAF mutations by multiplex digital PCR.
    Andersen RF; Jakobsen A
    Clin Chim Acta; 2016 Jul; 458():138-43. PubMed ID: 27181912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
    Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
    J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients.
    Taly V; Pekin D; Benhaim L; Kotsopoulos SK; Le Corre D; Li X; Atochin I; Link DR; Griffiths AD; Pallier K; Blons H; Bouché O; Landi B; Hutchison JB; Laurent-Puig P
    Clin Chem; 2013 Dec; 59(12):1722-31. PubMed ID: 23938455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
    Zimmer L; Barlesi F; Martinez-Garcia M; Dieras V; Schellens JH; Spano JP; Middleton MR; Calvo E; Paz-Ares L; Larkin J; Pacey S; Venturi M; Kraeber-Bodéré F; Tessier JJ; Eberhardt WE; Paques M; Guarin E; Meresse V; Soria JC
    Clin Cancer Res; 2014 Aug; 20(16):4251-61. PubMed ID: 24947927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
    Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.
    Tsao SC; Weiss J; Hudson C; Christophi C; Cebon J; Behren A; Dobrovic A
    Sci Rep; 2015 Jun; 5():11198. PubMed ID: 26095797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.
    Mostert B; Jiang Y; Sieuwerts AM; Wang H; Bolt-de Vries J; Biermann K; Kraan J; Lalmahomed Z; van Galen A; de Weerd V; van der Spoel P; Ramírez-Moreno R; Verhoef C; Ijzermans JN; Wang Y; Gratama JW; Foekens JA; Sleijfer S; Martens JW
    Int J Cancer; 2013 Jul; 133(1):130-41. PubMed ID: 23233388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue.
    Kwon MJ; Lee SE; Kang SY; Choi YL
    Pathol Res Pract; 2011 Dec; 207(12):762-8. PubMed ID: 22070922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
    Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.
    Li HT; Lu YY; An YX; Wang X; Zhao QC
    Oncol Rep; 2011 Jun; 25(6):1691-7. PubMed ID: 21424126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
    Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
    Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S
    Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput screening of extended RAS mutations based on high-resolution melting analysis for prediction of anti-EGFR treatment efficacy in colorectal carcinoma.
    Ishige T; Itoga S; Sato K; Kitamura K; Nishimura M; Sawai S; Matsushita K; Suzuki K; Ota S; Miyauchi H; Matsubara H; Nakatani Y; Nomura F
    Clin Biochem; 2014 Dec; 47(18):340-3. PubMed ID: 25262986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of melting analysis with TaqMan probes for detection of KRAS, NRAS, and BRAF mutations.
    Botezatu IV; Nechaeva IO; Stroganova АМ; Senderovich AI; Kondratova VN; Shelepov VP; Lichtenstein AV
    Anal Biochem; 2015 Dec; 491():75-83. PubMed ID: 26384642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimisation of robust singleplex and multiplex droplet digital PCR assays for high confidence mutation detection in circulating tumour DNA.
    Rowlands V; Rutkowski AJ; Meuser E; Carr TH; Harrington EA; Barrett JC
    Sci Rep; 2019 Sep; 9(1):12620. PubMed ID: 31477768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer.
    Yokota T; Shibata N; Ura T; Takahari D; Shitara K; Muro K; Yatabe Y
    Transl Res; 2010 Aug; 156(2):98-105. PubMed ID: 20627194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer.
    Lu W; Wei H; Li M; Wang H; Liu L; Zhang Q; Liu L; Lu S
    Mol Med Rep; 2015 Jul; 12(1):1219-24. PubMed ID: 25815786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.